SCHEMBL20157484

SCHEMBL20157484

COc1cc(C(=O)c2ccc(C)cc2Br)ccc1F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
CYP1A2 P05177 2/20 0.44
CYP2C19 P33261 2/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44
TSHR P16473 1/20 0.44
HPGD P15428 2/20 0.43
CYP2D6 P10635 1/20 0.43
HTT P42858 3/20 0.42
MAPT P10636 3/20 0.42
NPSR1 Q6W5P4 1/20 0.42
SLC22A6 Q4U2R8 1/20 0.42
SLC22A8 Q8TCC7 1/20 0.42
NPC1 O15118 2/20 0.41
POLB P06746 2/20 0.41
MAPK1 P28482 2/20 0.40
KMT2A Q03164 2/20 0.40
RAB9A P51151 2/20 0.40
LMNA P02545 1/20 0.40
TUBB4A P04350 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sulfamide SCHEMBL21352056 0.94 ALDH1A1 (0.43) ALDH1A1CYP1A2CYP2C19CYP3A4CYP2C9
SCHEMBL20158084 0.89 HTT (0.54) ALDH1A1CYP1A2CYP2C19CYP3A4CYP2C9
SCHEMBL20157483 0.86 ALDH1A1 (0.50) ALDH1A1CYP1A2CYP2C19CYP3A4CYP2C9
SCHEMBL21362528 0.84 LCK (0.42) ALDH1A1CYP1A2CYP2C19CYP2C9HPGD
SCHEMBL21564805 0.84 ALDH1A1 (0.48) ALDH1A1CYP1A2CYP2C19CYP3A4CYP2C9
SCHEMBL20157647 0.83 ALDH1A1 (0.44) ALDH1A1CYP1A2CYP2C19CYP3A4CYP2C9
SCHEMBL20157608 0.83 ALDH1A1 (0.44) ALDH1A1CYP1A2CYP2C19CYP3A4CYP2C9
SCHEMBL25340250 0.81 NPC1 (0.50) ALDH1A1CYP1A2CYP2C19CYP3A4CYP2C9
SCHEMBL21362791 0.81 ALDH1A1 (0.44) ALDH1A1CYP1A2CYP2C19CYP3A4CYP2C9
SCHEMBL21362766 0.79 ALDH1A1 (0.41) ALDH1A1CYP1A2CYP2C19CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190284192-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. (CN) 2019-09-19 US disclosed
US-20190284192-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. (CN) 2019-09-19 US disclosed
EP-3539960-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF Luoxin Pharmaceutical (Shanghai) Co., Ltd. (CN) 2019-09-18 EP disclosed
EP-3539960-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF Luoxin Pharmaceutical (Shanghai) Co., Ltd. (CN) 2019-09-18 EP disclosed
WO-2018086605-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF 山东罗欣药业集团股份有限公司 2018-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190284192-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF MYC, BRD1, BRD3 ALDH1A1 4457/4885CYP1A2 4059/4885CYP2C19 4270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.